Document is current

Article History

Received: 26 August 2025

Accepted: 3 June 2026

First Online: 24 June 2026

Declarations

Ethics approval and consent to participate: The study was approved by an Institutional Review Board (IRB) of the University of Gondar, College of Medicine and Health Science, Institute of Public Health (Reference number: /IPH/3110/2024). A support letter was obtained from the Amhara Public Health Institute, the North Gojjam Zone Health Department, and the Yilmana Densa district health office. Written informed consent was obtained from each study participant after clearly explaining the purpose, benefits, and risks of the study. For participants younger than 18 years of age, written consent was obtained from their parents or caregivers, and assent was obtained from the participants. The data were anonymized, and the data collection tool did not include personal identifiers such as names or addresses; instead, unique codes were used to keep participants' confidentiality. Participants were informed of their full right to withdraw from the study at any stage. Health education regarding the risks of non-adherence and the importance of completing the PQ treatment course was provided to non-adherent participants. Furthermore, participants with leftover pills were counseled to complete the remaining doses.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.